Assessing AI Preparedness in Drug Discovery

Through interviews with stakeholders across different sized drug discovery companies with varying levels of existing AI integration, we gained insights into the sector's current use of AI and the challenges faced in adopting AI in drug discovery. Key challenges identified included shortages of high-quality data, technical expertise, and infrastructure, compounded by resistance to change within the industry.

To gather further insights, we facilitated an advisory group meeting of drug discovery experts from academic spin‑outs and SMEs. This meeting resulted in a prioritised list of issues that the drug discovery industry will need to address, and yielded ideas for projects that MDC could initiate to overcome them and elevate the ability of the sector to gain value from AI.

The project should yield initiatives that make AI more accessible for SMEs in the drug discovery sector and enable more efficient and innovative drug discovery processes.